Fort Lee, NJ., (Uptick Newswire – August 28, 2017) – Herborium Group, Inc. (OTCMKTS:HBRM), www.Herborium.com, a Botanical Therapeutics® Company and the provider of unique all botanical medicinal products (Botanical Therapeutics®) announced today that it has officially committed to expanding into the hemp based products market. This expansion is backed by a Reg A Offering that will fund the Company’s already established, as well as new projects monetization, with up to $700,000 for product development, marketing and distribution. The Reg A will be funded by institutional and accredited investors in an equity based, non-convertible debt offering.
Herborium’s hemp and CBD based expansion will focus on partnerships with selected domestic and international hemp, CBD manufacturers who have proven, ready for market products but lack the marketing know-how and capabilities represented by Herborium. Additionally, the Company will work with hemp and CBD extractors to develop proprietary products for Herborium under its own soon to be announced brand. The Company has been conducting due diligence on several hemp, CBD companies and expects to move forward with one or more products once due diligence is complete.
Herborium’s unique know how of the herbal science and industry as well as its marketing expertise and resources make the Company an attractive partner in the growing hemp CBD market. Herborium intends to leverage this expertise and resources to continue its growth and expansion in the global herbal medicine and dermaceuticals market which is projected to reach $115 billion by 2020.
About Herborium Group, Inc.
Herborium Group, Inc. is a botanical therapeutics® company that develops, licenses and markets proprietary, botanical based medicinal products to consumers and healthcare professionals. The Company’s business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage. Herborium has secured a pipeline of botanical ingredients based products in the areas of dermatological needs, wellness and energy, prostate health, women’s health and selected sexual disorders Herborium Group sells its products in the United States, the United Kingdom, and continental Europe through a network of distributors, specialty retailers, and ecommerce. For more information, please visit www.herborium.com, www.acnease.com, www.acnease.fr and www.acneassp.com.
Safe Harbor Statement
This release contains forward-looking statements with respect to the results of operations and business of Herborium Group, Inc., which involves risks and uncertainties. The Company’s actual future results could materially differ from those discussed. The Company intends that such statements about the Company’s future expectations, including future revenues and earnings, and all other forward looking statements be subject to the “Safe Harbors” provision of the Private Securities Litigation Reform Act of 1995.
Source: Uptick Newswire